CYP2C19 and major depressive disorder: In contrast, Fabbri and colleagues (Fabbri et al. 2018) found in a meta-analysis that CYP2C19 poor-metabolizers had higher side-effects compared to extensive metabolizers at weeks 2–4, however, also showed higher symptom improvement and remission in major depression when treated with citalopram or escitalopram.